Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07668752

A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation

The purpose of this study is to compare the effectiveness, safety and tolerability of GFH375 versus docetaxel in participants with KRAS G12D-mutant non-small cell lung cancer (NSCLC).

GFH375 is an oral, highly selective, non-covalent small-molecule inhibitor targeting the KRAS G12D mutation. Preclinical studies showed GFH375 strongly blocks KRAS-driven signaling and cancer cell growth, and demonstrated anti-tumor activity in NSCLC animal models. Docetaxel is a chemotherapy drug for locally advanced or metastatic NSCLC.

This is an open-label, randomized controlled trial. Both participant and study doctor will know which study medication each participant receives.

After enrollment, participant will be randomly assigned to either the GFH375 group or docetaxel group by chance. Neither participant nor study doctor can pick your treatment group. You have a two-thirds chance to receive GFH375 and a one-third chance to receive docetaxel.

* GFH375 group: Take GFH375 tablets by mouth once daily as scheduled; each treatment cycle lasts 21 days. * Docetaxel group: Receive docetaxel via intravenous infusion at 75 mg/m² once every 3 weeks.

Study treatment will continue until cancer gets worse, participant can't tolerate the study treatment, or other conditions make participant unable to keep receiving study treatment.

Some participants on docetaxel may be able to switch to GFH375 during the study if their cancer becomes worse. There will be safety checks at each visit, and the doctors will continue to check for medical problems and participant 's wellbeing throughout the study. Participants will continue to have scans of their tumor every 6 weeks for the first year, then every 9 weeks until their cancer becomes worse. After participant's cancer becomes worse, clinic staff will telephone participant every 3 mouths to check on their cancer.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

KRAS G12D Mutation Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Lung Diseases Lung Neoplasms NSCLC (Non-small Cell Lung Cancer) Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Shanghai Lung Cancer Center, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, 201210, China

Location contact

Shun Lu, MD

CONTACT

[email protected]

8621-22200000*5341

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1. Voluntary participation in the study and signed informed consent form (ICF).
  • 2. Age ≥ 18 years at the time of signing the ICF; male or female.
  • 3. Histologically or cytologically confirmed locally advanced unresectable or metastatic non small cell lung cancer (NSCLC).
  • 4. Participants must provide adequate and qualified tumor tissue slides samples or agree to undergo tumor biopsy to obtain tissue samples for central laboratory confirmation of KRAS G12D mutation.
  • 5. Disease progression or intolerance to toxicity after at least one prior line of platinum based chemotherapy and anti PD 1/PD L1 antibody therapy.
  • 6. At least one measurable target lesion according to RECIST version 1.1.
  • 7. Investigator assessed life expectancy ≥ 12 weeks.
  • 8. Adequate organ function.
  • 9. Ability to communicate well, comply with scheduled follow up visits, and adhere to protocol requirements.

Exclusion criteria

  • 1. Presence of other driver gene mutations in NSCLC, or concurrent other KRAS or RAS mutations.
  • 2. Other malignancy that has progressed or required treatment within 3 years prior to randomization.
  • 3. Leptomeningeal metastasis, or symptomatic or progressive central nervous system (CNS) metastasis.
  • 4. Existing or potential severe bone injury due to bone metastasis, or uncontrolled pain related to bone metastasis.
  • 5. Prior treatment with KRAS G12D targeted therapy or pan RAS/KRAS targeted therapy.
  • 6. Prior treatment with docetaxel as part of systemic therapy.
  • 7. Radiotherapy within 4 weeks prior to randomization, or other local anti tumor therapy within 4 weeks prior to randomization.
  • 8. Other anti tumor therapy within 28 days or 5 half lives prior to randomization, or cell therapy within 3 months prior to randomization.
  • 9. Clinically significant severe cardiovascular disease.
  • 10. Stroke or other severe cerebrovascular disease within 6 months prior to randomization.
  • 11. Major acute or chronic infectious disease.
  • 12. Other poorly controlled systemic diseases.
  • 13. Severe psychiatric or psychological disorder, or history of drug abuse, or severe alcohol abuse.
  • 14. Pregnancy or breastfeeding.
  • 15. Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.

Treatment and study plan

GFH375

Drug

GFH375 administered orally at the protocol-specified dose once daily. Each treatment cycle is 21 days.

docetaxel

Drug

Receive docetaxel via intravenous infusion at 75 mg/m² once every 3 weeks.

Primary outcomes

  1. Objective Response Rate(ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. as assessed by blinded independent central review (BICR)

    Time frame: From the first dose until the date of first documented CR or PR, assessed up to 24 months

    ORR is the proportion of participants whose best response is either complete response (CR) or partial response (PR) per RECIST v1.1 assessed by BICR.

  2. Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. as assessed by blinded independent central review (BICR)

    Time frame: From the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.

    PFS is defined as the time from the date of randomization until the date of documented radiographic disease progression per RECIST v1.1, as assessed by BICR or until death due to any cause, whichever comes first.

  3. Overall Survival (OS)

    Time frame: From the first dose until the date of death from any cause, whichever came first, assessed up to 36~48 months

    OS is defined as the time from the date of randomization until the date of death from any cause.

Secondary outcomes

  1. Objective Response Rate (ORR) per RECIST v1.1, as assessed by the investigator

    Time frame: From the first dose until the date of first documented CR or PR,assessed up to 24 months.

    ORR is defined as the proportion of participants whose best overall response (BOR) is rated as confirmed complete response (CR) or confirmed partial response (PR) per RECIST v1.1. as assessed by the investigator.

  2. PFS per RECIST v1.1. as assessed by the investigator

    Time frame: From the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.

    PFS is defined as the time from the date of randomization until the date of documented radiographic disease progression per RECIST v1.1 as assessed by the investigator or until death due to any cause, whichever comes first.

  3. DCR per RECIST v 1.1 as assessed by the investigator and the BICR

    Time frame: From the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.

    DCR is defined as the proportion of participants whose best overall response is rated as CR, confirmed PR or SD per RECIST v1.1 as assessed by the investigator and the BICR.

  4. DoR per RECIST v 1.1 as assessed by the investigator and the BICR

    Time frame: From the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.

    DOR is defined as the time from the date of first documented response (CR or PR subsequently confirmed) to the date of first documented PD per RECIST v1.1 as assessed by the investigator and the BICR or death due to any cause, whichever occurs first.

  5. TTR per RECIST v 1.1 as assessed by the investigator and the BICR

    Time frame: From the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.

    TTR is defined as the time from the date of randomization to the first documentation of objective response (confirmed CR or confirmed PR) per RECIST v1.1. as assessed by the investigator and the BICR.

  6. Number of Participants with Adverse Events (AEs)

    Time frame: From the first dose until 30 days after the last dose, assessed up to 24 months.

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

  7. Severity of Adverse Events(AEs)

    Time frame: From the first dose until 30 days after the last dose, assessed up to 24 months.

    The severity of an adverse event is commonly graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE )5.0.

  8. Incidence of AEs that result in treatment discontinuation, treatment interruption, or dose reduction.

    Time frame: From the first dose until 30 days after the last dose, assessed up to 24 months.

    AEs that result in treatment discontinuation, treatment interruption, or dose reduction.

  9. Severity of adverse events (AEs) leading to treatment discontinuation, treatment interruption, and dose reduction.

    Time frame: From the first dose until 30 days after the last dose, assessed up to 24 months.

    Severity of adverse events (AEs) leading to treatment discontinuation, treatment interruption, and dose reduction per CTCAE 5.0.

  10. Time to deterioration in NSCLC symptoms evaluated via European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module (EORTC QLQ-LC13) items

    Time frame: From the first dose until 30 days after the last dose, assessed up to 24 months.

    Time to deterioration is defined as time between randomization and the first occurrence of a meaningful deterioration in the corresponding EORTC QLQ-LC13 items score compared with the baseline score. EORTC QLQ-LC13 is a lung-cancer specific module that serves as an additional 13 item questionnaire to the general EORTC cancer questionnaire. It consists of 3 items to assess dyspnea, and 10 single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. Scores range from 0 to 100. A high score for a symptom scale/item represents a high level of symptomatology/problems.

  11. Time to Worsening measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) items

    Time frame: From the first dose until 30 days after the last dose, assessed up to 24 months.

    Time to Worsening is defined as time between randomization and the first occurrence of a meaningful worsening in the composite EORTC QLQ-C30 items scores compared with the baseline score. EORTC-QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." For functional scales, higher scores indicate better functioning, while for symptom scales/items, higher scores indicate worse symptoms.

  12. Change from baseline in EORTC QLQ-C30

    Time frame: From the first dose to week12.

    The EORTC-QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." For functional scales, higher scores indicate better functioning, while for symptom scales/items, higher scores indicate worse symptoms.

  13. Change from baseline in EORTC QLQ-LC13

    Time frame: From the first dose to week12.

    EORTC QLQ-LC13 is a lung-cancer specific module that serves as an additional 13 item questionnaire to the general EORTC cancer questionnaire. It consists of 3 items to assess dyspnea, and 10 single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. Scores range from 0 to 100. A high score for a symptom scale/item represents a high level of symptomatology/problems.

  14. Pharmacokinetics (PK) of GFH375: Trough concentration after multiple dosing

    Time frame: From the first dose to Cycle 6 Day 1(each cycle is 21 days).

    Trough concentration will be recorded from plasma samples collected.

  15. PK of GFH375: Peak concentration after multiple dosing

    Time frame: From the first dose to Cycle 6 Day 1(each cycle is 21 days).

    Peak concentration will be recorded from plasma samples collected.

Study contacts

Contact information is provided by the study sponsor or research team.

Junnan Dong

CONTACT

[email protected]

+8615521118409

Yolanda Zeng

CONTACT

[email protected]

+8618073129952

Sponsors and collaborators

Lead sponsor

Genfleet Therapeutics (Shanghai) Inc.

Industry

Registry information

Official study title

A Phase III, Randomized, Open-Label, Multicenter Study to Evaluate GFH375 Versus Docetaxel in Participants With Locally Advanced and Unresectable or Metastatic Non-Small Cell Lung Cancer With KRAS G12D Mutation Failed Prior Standard Therapy

Important dates

Study start
2026
Primary completion
2030
Study completion
2031
First posted
Jun 25, 2026
Registry last updated
Jun 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.